Top Markets
#1 ADO Protocol ADO Protocol +194.43%
#2 Islamic Coin Islamic Coin +155.35%
#3 GoPlus Security GoPlus Security +40.15%
#4 GAIB AID GAIB AID +24.67%
#5 Victoria VR Victoria VR +19.28%
#6 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.36%
#7 Wrapped NXM Wrapped NXM +15.19%
#8 Verus Coin Verus Coin +13.65%
#9 Pons Pons +12.72%
#10 o1.exchange o1.exchange +11.86%
Coin of the day
ADO Protocol ADO Protocol
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
TME Pharma N.V. TME Pharma N.V.

TME Pharma N.V.

ALTME
Classifica tra le azioni #33517
TME Pharma N.V., a biopharmaceutical company in the clinical development stage... TME Pharma N.V., a biopharmaceutical company in the clinical development stage based in Berlin, Germany, is dedicated to pioneering innovative therapeutic solutions for cancer. The company leverages its unique Spiegelmer platform to advance a pipeline of investigational drug candidates. Its primary oncology asset, NOX-A12, is currently being evaluated in clinical studies as a combination therapy for a range of challenging cancers, including metastatic pancreatic and colorectal cancer, glioblastoma, and myeloma. Beyond its cancer-focused efforts, TME Pharma also developed NOX-E36, which has successfully concluded Phase 1/2 clinical trials for diabetic nephropathy. The company has formed a strategic collaboration with Merck Sharp & Dohme Corp. to explore NOX-A12 in combination with Keytruda and two different chemotherapy protocols as a second-line intervention for patients battling metastatic pancreatic cancer. Founded in 1997, the organization adopted its current name, TME Pharma N.V., in July 2022, having previously operated as NOXXON Pharma N.V.
Prezzo delle azioni
$0.0794724
Capitalizzazione di mercato
$7.49M
Variazione (1 giorno)
4.69%
Variazione (1 anno)
-38.28%
Paese
DE
Scambia TME Pharma N.V. (ALTME)

Categoria

Healthcare
Ricavi di TME Pharma N.V. (ALTME)
Ricavi nel Aug 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di TME Pharma N.V., i ricavi attuali dell'azienda (TTM) sono pari a 0. Nel 2026, l'azienda ha registrato ricavi di 0 uguale a i ricavi dell'anno 2026, che erano pari a 0. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per TME Pharma N.V. da 2026 a 2026
Ricavi alla fine di ogni anno
Anno Ricavi Cambia
Non abbastanza dati per le date fornite.
Ricavi di aziende simili o concorrenti
Azienda Ricavi Differenza nei ricavi Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE